Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ]: Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ]: Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ]: Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010
Mon, September 27, 2010
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010

RXi Pharmaceuticals to Webcast Presentation at the 9th Annual BIO Investor Forum

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. tation-at-the-9th-annual-bio-investor-forum.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Companya™s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the 9th Annual BIO Investor Forum on Wednesday, October 6, 2010 at 2:30 p.m. PT in San Francisco.

A live webcast of the presentation will be available from the aInvestor Relationsa section of the Company's redesigned website, [ www.rxipharma.com ], which will be launched next week. A replay of the presentation will be available for 30 days.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. [ www.rxipharma.com ]